Is PTD-DBM safe to take?
PTD-DBM: The Revolutionary Hair Loss Treatment
PTD-DBM is a synthetic peptide that inhibits the action of CXXC5, a protein that is linked to hair loss. This helps to limit hair loss, which is a desirable outcome. When CXXC5 connects with the Dishevelled protein, it can cause hair loss by blocking follicle development and hair regeneration. As a result, preventing the interaction of these two proteins will aid to stimulate hair regrowth and hair neogenesis. This is the primary mechanism behind PTD-DBM. PTD-DBM targets the WNT/beta-catenin pathway directly, which is a pathway that has been highly conserved throughout the course of evolution and is responsible for essential cellular functions such as proliferation and stem cell renewal. This interaction between CXXC5 and Dishevelled is disrupted by PTD-DBM.
Why Would You Want to Use PTD-DBM?
Wound-induced hair follicle neogenesis
What You Absolutely Must Be Aware Of
When administered topically directly on the scalp, PTD-DBM is at its most effective in stimulating hair regeneration as well as hair neogenesis. This is because PTD-DBM is a keratin protein. Combined therapy of PTD-DBM with valproic acid, an activator of the sWNT beta-catenin signalling pathway, can also assist to further increase hair regeneration and prevent hairs loss.
Patient Benefits
● Prevents the most common kind of baldness prevalent kind of hair loss in both men and women
● Restore damaged skin tissues, particularly in balding human scalps.
● Accelerated hair regrowth
● New follicle development in regions of baldness
● Prevents and corrects hair loss
● Accelerates wound healing
Possible Applications of the PTD-DBM Peptide
The use of PTD-DBM in the treatment of androgenic alopecia
Androgenetic alopecia is also known as male pattern baldness. It is an increasingly recognised disorder having substantial physical and psychological impacts on the victims. It is a disorder that becomes progressively worse and causes a distinct pattern of hair loss. It starts with the recession of the frontal hairline and hair loss in the vertex or crown region of the head. The vertex and frontal portions of the scalp eventually become completely bald as the condition worsens.
There are three stages involved in the development of hair. These are known as the anagen phase (the phase of growth), the catagen phase (the phase of regression), and the telogen phase (resting phase). The excessive production of androgens, specifically testosterone, causes the anagen phase to last for a shorter amount of time. It resulted in hair that was thinner, had a faster turnover rate, and accelerated hair loss. The anagen phase typically lasts for several years; but, in cases of androgenetic alopecia, it can last for as little as a few months.
The Wnt/-catenin signalling pathway is the most important of the many different cellular processes that occur in hair follicles and are responsible for controlling hair development. This signalling pathway starts with the release of Wnt proteins. These proteins connect with the Low-Density Lipoprotein-Related Protein (LRP), which in turn deactivates the glycogen synthase kinase-3 (GSK-3) enzyme. In the hair follicle, GSK-3 is an enzyme that is responsible for deactivating the -catenin protein.
Once stabilised, β-catenin connects with the T-cell factor (TCF)/lymphoid enhancer factor (LEF) (LEF). The proteins created by the activation of β-catenin-TCF/LEF lead to the control of hair follicle cellular proliferation.
Throughout the course of their investigation, Professor Kang-Yell Choi and the rest of the team became aware of a certain pattern. They discovered that a particular protein with the name CXXC-type zinc finger protein 5 (CXXC5) was overexpressed in the scalps of individuals who suffered from alopecia. CXXC5 stimulates the signalling pathways leading to a downregulation of Wnt/β-catenin. This discovery has been verified by research conducted on animals, namely mice, where the absence of CXXC5 expression prevented the development of male-pattern baldness symptoms.
The interaction of CXXC5 with another kind of protein known as Dvl protein is necessary for its function. The Wnt/-catenin signalling pathway is inhibited as a result of an interaction between the proteins CXXC5 and Dvl known as a Protein-Protein Interaction (PPI). Downregulation of the Wnt/-catenin pathway is associated with an interference in the development of new hair follicles as well as the proliferation of existing follicles.
PTD-DBM is an inhibitor of the protein-to-protein interaction caused by CXXC5 and Dvl (PPI). It results in an acceleration of the proliferation of hair follicles. In addition, as a consequence of this interaction, the anagen phase of the hair cycle is maintained for a longer period of time by the hair follicles. This technique leads to healthier and thicker hair. This method not only stops severe hair loss, but it also has the potential to be a successful therapy for androgenetic alopecia. The activity of PTD-DBM amplifies even more when taken in conjunction with drugs such as valproic acid.
ACCELERATED WOUND HEALING
The Wnt/-catenin pathway is an essential component in the process of wound healing and the formation of fibrosis in skin breaches. CXXC-type zinc finger protein 5 is one of the regulators that are involved in this pathway (CXXC5). It regulates itself by a process of negative feedback. The activity of the Wnt/-catenin signalling pathway is slowed down as a result of an interaction between CXXC5 and the Disheveled (Dvl) protein. The skin wounds of CXXC5 knockout mice healed more quickly than those of wild-type mice. In addition to that, their levels of keratin and collagen production are elevated.
It is the responsibility of PTD-DBM to thwart the activities of the CXXC5-Dvl domain. It achieves that by preventing the Protein-Protein Interaction (PPI) between CXXC5 and Dvl proteins. This achievement results in an upregulation of the Wnt/β-catenin pathway. This upregulation results in improved skin wound healing by raising the production of keratin and collagen and by speeding the process of dermal fibrosis.
This characteristic of PTD-DBM may have a variety of repercussions depending on the context. PTD-DBM may be utilised in the aesthetics field in cases that need for faster wound healing. In instances where wound healing is hampered for a variety of reasons, PTD-DBM may potentially be utilised as a treatment option.
DOES PTD-DBM HAVE ANY SIDE EFFECTS?
PTD-DBM has yet not received approval from the FDA for use for baldness or to accelerate wound healing. Despite this, the findings of the investigation are encouraging, and the product will likely be authorised very soon. The fact that it has a good safety profile is still another thing that might help it get approved. According to the findings of the researchers, PTD-DBM has an outstanding safety profile and does not produce any harmful side effects.
CONCLUSION
In conclusion, PTD-DBM is a peptide that has a lot of potential. It has the potential to completely change the landscape of hair growth and regeneration in the future. It’s possible that this may go down in history as the greatest important step forward in the treatment of male-pattern baldness.
